Seattle Genetics Astellas get FDA breakthrough therapy status for Padcev plus Keytruda to treat bladder cancer

Seattle Genetics, Astellas get FDA breakthrough therapy status for Padcev plus Keytruda to treat bladder cancer

The breakthrough therapy status enables Padcev plus Keytruda combination to treat patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in

More From BioPortfolio on "Seattle Genetics, Astellas get FDA breakthrough therapy status for Padcev plus Keytruda to treat bladder cancer"